CytoDyn
1111 Main Street
Suite 660
Vancouver
Washington
98660
United States
Website: http://www.cytodyn.com/
287 articles with CytoDyn
-
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor
5/13/2022
CytoDyn Inc. announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors.
-
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”
4/12/2022
CytoDyn Inc. today announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
The U.S. FDA placed a partial hold on CytoDyn's HIV program and a full clinical hold on its COVID-19 program in the U.S.
-
CytoDyn to Hold Webcast to Provide Company Update - Mar 30, 2022
3/30/2022
CytoDyn Inc. announced that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.
-
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program
3/30/2022
CytoDyn Inc. announced that the U.S. Food and Drug Administration has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States.
-
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.
-
The company's focus is to find somebody with considerable pharmaceutical industry experience to help advance regulatory and commercialization initiatives for leronlimab.
-
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
1/25/2022
Today the Board of Directors (“the Board”) of CytoDyn Inc. announced a leadership transition plan.
-
Sixty-three percent of patients met the primary endpoint of a 2-point or greater improvement in disease severity without worsening of fibrosis.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
1/13/2022
CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for , Thursday, January 13, 2022 and will provide an update at a future date.
-
CytoDyn to Hold Webcast and Live Q/A on January 13
1/11/2022
CytoDyn will host an investment community webcast to discuss and provide updates with regard to NASH data results, Cancer, COVID-19, HIV BLA, and finances of the Company on Thursday, January 13, 2022.
-
The NASH trial achieved the primary endpoint of proton density fat fraction and the secondary endpoint of cT1.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
1/5/2022
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial.
-
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
12/22/2021
CytoDyn Inc. today announced that the U.S. District Court for the District of Maryland has granted CytoDyn’s previously-announced motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research (“Amarex”), the Company’s former Contract Research Organization (“CRO”).
-
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
12/21/2021
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that it has received a positive response from the U.S. Food and Drug Administration (“FDA”) to conduct a Phase 3, randomized, double blind, placebo controlled trial to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for Invasive Mechanical Ventilation ("IMV”) or Extracorporeal Membrane Oxygenation (“ECMO”).
-
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
12/13/2021
CytoDyn Inc. announced today additional preliminary results to date from the 20 patients who have completed the open-label portion of the Phase 2 trial for NASH (Nonalcoholic steatohepatitis).
-
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
12/9/2021
CytoDyn will request FDA permission to charge HIV MDR patients under expanded access.